A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:

##STR00001##

Pleuromutilin derivative compounds of the following formula (I), and uses thereof for the treatment of diseases mediated by microbes, are disclosed:

##STR00001##

Pleuromutilin derivative compounds of the following formula (I), and uses thereof for the treatment of diseases mediated by microbes, are disclosed:

##STR00001##

Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.AA, n, ring A, X.sup.1, L, m, X.sup.2, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X, and R.sup.6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables R.sup.AA, n, ring A, X.sup.1, L, m, X.sup.2, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X, and R.sup.6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The present invention provides compounds of formula (I):

##STR00001##

or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and R.sup.a are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.

The present invention provides compounds of formula (I):

##STR00001##

or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and R.sup.a are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.